Addiction Medicine for Liver Care Providers

DESCRIPTION

There is growing interest among hepatology providers in incorporating addiction medicine skills in the evaluation of patients with addiction-related liver diseases, particularly alcohol-associated liver disease. Recent studies have shown an association between receipt of addiction treatment and improvements in liver-related outcomes in patients with alcohol-associated liver disease. Furthermore, a survey by the AASLD Alcohol-Associated Liver Disease Special Interest Group examining hepatology provider knowledge and attitudes toward the identification and treatment of alcohol use disorder revealed that 90% of respondents felt the need for additional training. Substance use disorders beyond alcohol use disorder can impact candidacy for liver transplantation as well as other liver-related outcomes. Given the rising prevalence of alcohol-associated liver disease and high burden of substance use disorders in the United States, arming liver care providers with skills to address addiction among their patients can have a significant clinical and public health impact. The purpose of this course is to provide a focused overview of key addiction medicine topics and how they relate to the care of patients with chronic liver disease.  

KEY TOPIC AREAS
-Biological Basis and Approach to Substance Use Disorders [30 minutes]
-Screening, Diagnosis and Monitoring of Substance Use Disorders [30 minutes]
-Behavioral and Pharmacological Therapies for Substance Use Disorders [30 minutes]
-Management of Alcohol Use Disorder [45 minutes]
-Management of Opioid Use Disorder [40 minutes]
-Management of Tobacco Use Disorders [30 minutes]
-Management of Cannabis, Stimulant and Sedative-Hypnotic Use Disorders [45 minutes]
-Integrating Addiction and Hepatology Care [40 minutes]

Release date: January 25, 2022
Expiration date: January 24, 2025
Time to complete each module: 30-45 minutes

CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 6.00 AMA PRA Category 1 Credits™  
Continuing Education (CE): For a maximum of 6.00 Contact Hour 
You may only earn one Continuing Education Credit type - either CME or CE

Maintenance of Certification (MOC): For a maximum of 6.00 MOC Points

COMPONENTS
Online presentations comprised of:
-Eight online narrated modules 30 to 45 minutes in length
-Pre- and Post-test [5-10 minutes per module]
-Evaluation for CME or CE credit offering [5-10 minutes]

DIRECTIONS
Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

COPYRIGHT 
All faculty in this activity have given their permission for publication ©2022 AASLD. 

CONTACT INFORMATION 
For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

After the completion of this course, the learner will be able to:

• Describe the biological basis, epidemiology and general approach to addiction treatment
• Identify and facilitate treat for common substance use disorders, including alcohol use disorder, opioid use disorder, tobacco use disorder and others
• Recognize ways of integrating addiction treatment into hepatology care settings

This course was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Physician Assistants/Physician Associates
Transplant Coordinators
Surgeons
Fellows/Trainees
Primary Care Physicians
Other healthcare providers

CREDITS OFFERED 
Continuing Medical Education (CME): For a maximum of 6.00 AMA PRA Category 1 Credits™ 
Maintenance of Certification (MOC): For a maximum of 6.00 MOC Points
Continuing Education (CE): For a maximum of 6.00 Contact Hours

ACCREDITATION AND DESIGNATION STATEMENTS  
Continuing Medical Education (CME)  The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Education (Nursing Contact Hours)  
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 6.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME CREDITS 
Physicians and other health care professionals for a maximum of 6.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by January 24, 2025. 

CLAIMING CE CREDITS
Nurses for a maximum of 6.00 contact hours for this enduring continuing education material must be completed by January 24, 2025. 

CLAIMING ABIM MOC POINTS  
Physicians seeking ABIM MOC credit must complete the enduring material by January 24, 2025. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through January 2025 for individuals who successfully complete MOC.

HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

             o    Complete the pre-tests

             o    Watch video presentations

             o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

             o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning. The faculty, organizers and reviewers have reported the following disclosures:

Sarah Wakeman, MD
Faculty
Research Support: Optum Labs
Advisory Committees or Review Panels: Celero Systems
Author: UpToDate

Jeffrey Samet, MD, MA, MPH
Faculty
Nothing to disclose

Dana Cavallo, PhD
Faculty
Nothing to disclose

Melissa Weimer, DO, MCR, FASAM
Faculty
Consulting: Path, CCM Inc.
Advisory Committees or Review Panels: American Society of Addiction Medicine
Grant/Research Support: NIH NIDA

Tiffany Lu, MD, MS
Faculty
Grant/Research Support: HRSA, SAMHSA, NIH NIDA
Author: UpToDate

Stephen Baldassarri, MD
Faculty
Nothing to disclose

Linda Peng, MD
Faculty
Nothing to disclose

Gerald (Scott) Winder, MD
Faculty
Nothing to disclose

Lamia Haque, MD, MPH
Online Learning Committee/Organizer/Reviewer
Nothing to disclose 

Oren K. Fix, MD, MSc, FAASLD  
Online Learning Committee/Organizer/Reviewer
Nothing to disclose

Andrew Paul Keaveny, MD, FRCPI, FAASLD 
Online Learning Committee/Organizer/Reviewer
Advisory Committees or Review Panels: UpToDate; American Board of Internal Medicine
Grant/Research Support: Mallinckrodt Medical Inc; HepQuant LLC. (Title of study: The SHUNT-V Study for Varices); Regeneron Pharmaceuticals; Gabriel House of Care

Omar Mousa, MD 
Online Learning Committee/Organizer/Reviewer
Nothing to disclose 

Nicole E. Rich, MD 
Online Learning Committee/Organizer/Reviewer
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AstraZeneca

Robert Mitchell-Thain
Online Learning Committee/Reviewer
Nothing to disclose

Arnab Mitra, MD 
Online Learning Committee/Reviewer
Nothing to disclose

Rohit S. Satoskar, MD, FAASLD 
Online Learning Committee/Reviewer
Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: Pfizer

Megan Glynn
Online Learning Committee
Nothing to disclose

Sanjiv Harpavat, MD, PhD 
Online Learning Committee
Data Safety Monitoring Board for Industry or Commercial Enterprise: Syneos

Paul Martin, MD, FAASLD
Online Learning Committee
Grant/Research Support: AbbVie, Thera and Mallinckrodt

Dominique Clayton 
AASLD Staff
Nothing to disclose

Sheryl Morgan 
Amedco LLC Staff
Nothing to disclose

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.